- $4.04bn
- $4.89bn
- $3.79bn
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
RCS - Redx Pharma Limited - Appointment of Chief Medical Officer
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
FTI Consulting Inc reports results for the quarter ended June 30 - Earnings Summary
FTI Consulting Q2 profit misses on higher direct costs
UnitedHealth says most home-health diagnoses were supported in 2025
Brief: FTI Consulting Appoints Financial Services Transactions Expert Emanuele Grasso To Lead In Italy
FTI Consulting Q1 revenue growth beats estimates; outlook reaffirmed
Brief: FTI Consulting To Keep Steve Gunby As CEO After Dropping Succession Plan- FT
Brief: FTI Consulting Incremental Amendment Provides For $300 Million Term Loan - SEC Filing
RCS - Redx Pharma Limited - RXC008 Receives US FDA Fast Track Designation
RCS - Scotch Corner Dsgnr. - Intention to Float
FTI Consulting Q4 revenue up 11%, beats expectations
Media: Group of banks said to hire FTI as adviser for Raizen talks - Bloomberg News
Brief: Cybersecurity Expert Jason Smolanoff Joins Fti Consulting As A Senior Managing Director
Brief: FTI Consulting Expands Transactions Communications Capabilities With Two Senior Hires
RCS - Redx Pharma Limited - US FDA lifts Partial Clinical Hold on Zelasudil
FTI Consulting beats Q3 revenue estimates, raises FY forecast